Blog – Page 2 – PRAIS 2.0

Home
Blog

PAHO launches new resources to strengthen diabetes diagnosis, treatment, and control in primary health care

admin - 18:47, 12 de November de 202544

PAHO launches new resources to strengthen diabetes diagnosis, treatment, and control in primary health care

Cristina Mitchell

13 Nov 2025

COP30: PAHO Director call countries to implement the Belém Health Action Plan to build more resilient, inclusive health systems

admin - 17:53, 12 de November de 202536

COP30: PAHO Director call countries to implement the Belém Health Action Plan to build more resilient, inclusive health systems

Cristina Mitchell

13 Nov 2025

Update: FDA Encourages the Public to Follow Established Choking Rescue Protocols – FDA Safety Communication

Murilo Freitas - 05:00, 12 de November de 202553

These choking rescue protocols include abdominal thrusts (also called the “Heimlich” maneuver) for children and adults but not anti-choking devices.

http://www.fda.gov/medical-devices/safety-communications/update-fda-encourages-public-follow-established-choking-rescue-protocols-fda-safety-communication

Longtime FDA Innovator Appointed as Director of Center for Drug Evaluation and Research

Murilo Freitas - 21:19, 10 de November de 202550

Longtime FDA Innovator Appointed as Director of Center for Drug Evaluation and Research
http://www.fda.gov/news-events/press-announcements/longtime-fda-innovator-appointed-director-center-drug-evaluation-and-research

PAHO calls for regional action as the Americas lose measles elimination status

admin - 18:43, 9 de November de 202552

PAHO calls for regional action as the Americas lose measles elimination status

Cristina Mitchell

10 Nov 2025

HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy

Murilo Freitas - 17:17, 9 de November de 202543

HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy
http://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy

PAHO scales up its emergency health response across the Caribbean following Hurricane Melissa

admin - 22:33, 6 de November de 202558

PAHO scales up its emergency health response across the Caribbean following Hurricane Melissa

Cristina Mitchell

7 Nov 2025

La OPS y la Comisión Europea firman acuerdo para fortalecer la preparación y respuesta ante amenazas sanitarias transfronterizas

admin - 18:16, 6 de November de 202563

PAHO and European Commission’s Health Emergency Authority make deal to boost preparedness for cross-border health threats

Cristina Mitchell

7 Nov 2025

Amazon countries strengthen cooperation to tackle emerging zoonotic diseases

admin - 14:22, 6 de November de 202557

Amazon countries strengthen cooperation to tackle emerging zoonotic diseases

Cristina Mitchell

7 Nov 2025

Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples

Murilo Freitas - 05:00, 6 de November de 202563

FOR IMMEDIATE RELEASE – Nov. 6,2025 – LAKE ZURICH, Ill.— Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies is voluntarily recalling three lots (numbers 6133156, 6133194, 6133388) of Famotidine Injection, USP, 20 mg

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fresenius-kabi-issues-voluntary-nationwide-recall-three-lots-famotidine-injection-usp-20-mg-2-ml-10

PRAIS 2.0